Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly Growing Multi Billion Dollar Market

Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The company’s latest move expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical weight-loss solutions skyrockets across employers and consumers. Following the announcement, Dario’s shares surged nearly 14%, reflecting investor excitement over this significant growth opportunity.

The market for GLP-1 medications, driven by blockbuster drugs like Novo Nordisk’s Ozempic and Wegovy, is transforming how obesity and weight management are addressed. These medications have shown impressive results, leading to double-digit weight loss, but the rising costs are pushing employers to seek solutions that ensure better ROI. With 44% of large employers now covering obesity medications, according to a recent Mercer survey, Dario’s expanded offering provides an end-to-end program to improve employee health outcomes while managing costs.

Unlike many digital health providers, Dario’s solution integrates behavior change programs with physician oversight, ensuring that GLP-1 medications are prescribed to the right people and supported by sustainable lifestyle changes. This approach aims to prevent the all-too-common cycle of weight regain after medication use, a key concern for both individuals and employers. The new prescribing capability is a critical piece of the puzzle, enabling Dario to oversee the entire weight-loss journey and optimize long-term results.

Beyond employers, the direct-to-consumer market is another high-growth target for Dario. As more consumers seek out medical weight-loss options online, the company’s digital platform, combined with virtual care, offers an easily accessible, scalable solution to meet this demand. Additionally, pharmaceutical companies are increasingly seeking partners like Dario to provide data-driven insights and improve patient engagement, opening potential new revenue streams.

Dario’s move follows the success of GLP-1 giants Novo Nordisk and Eli Lilly, whose treatments have reshaped the market. However, while the market leaders focus on medications alone, Dario’s behavior-first model differentiates it by tackling the underlying habits that drive lasting weight loss.

As the GLP-1 market continues to expand, Dario’s integrated solution could position the company as a key digital health partner for employers, consumers, and pharma companies alike—tapping into one of healthcare’s most promising opportunities for growth.

Market Alerts are generated by Wall Street Wire’s news desk and summarize news developments. They include partner content on behalf of the mentioned issuer [DRIO]. They are not intended to serve as financial or investment advice. Please see our full terms, disclaimers and compensation disclosures here: redditwire.com/terms. Our alerts may include forward looking statements about the significance or impact an announcement or development may have on the future of a company or industry as well as other similar statements which may not come to fruition. We advise all readers refer to our full terms in the above link.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.